One of these useful substances is L-lysine-oxidase produced by Trichoderma fungi. A team of researchers from RUDN University developed a technology to incorporate this enzyme into a wound-healing gel. The method does not require expensive purification of the initial biological liquids and therefore is economically feasible.
"Modern-day microbiology is focused on physiologically active metabolic products of microorganisms. The fungi of the genus Trichoderma are well-studied, and the Trichoderma harzianum Rifai F-180 strain can produce large quantities of a protein called L-lysine-oxidase that has confirmed antiviral and anti-tumor properties. This opens a range of prospects for the development of new pharmaceutical forms that could be used to treat infections and skin damage," said Prof. Irina Smirnova, a PhD. in Biology, from Berezov Department of Biochemistry at RUDN University.
Based on the results of earlier studies, the team chose the optimal active ingredient concentration of 1 percent. When selecting additional components for the gel, the scientists followed a set of rules. The base of the gel had to match the active ingredient, support the activity of L-lysine-oxidase, secure easy application and storage, and cause no irritation. Following these principles, the team chose and tested three base options: methylcellulose, carbopol, and mARS.
The experiment was conducted on nine adult guinea pigs divided into groups of three. The skin of the animals was mechanically damaged, and 18 hours after that the team started the treatment. Each animal was treated with one of the three types of gel for two weeks. The product based on methylcellulose demonstrated the worst results with wounds healing for 9 to 10 days on average. The best results were registered in the group that received the carbopol-based gel: the wounds of the animals healed after 6 to 7 days.
"Based on the results of the experiment, we can confirm that 1 percent carbopol-based gel with the culture liquid of Trichoderma has advanced wound-healing properties. The next stage for us will be a pre-clinical trial. The new pharmaceutical form could be used in veterinary medicine to treat wounds, viral skin infections, and ocular herpes. Moreover, it could find application in medical cosmetology, gynecology, and skin cancer therapy," added Prof. Irina Smirnova from RUDN University.
MEDICA-tradefair.com; Source: RUDN University